https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:14913 Wed 11 Apr 2018 16:10:25 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46701 P < 0.0001) and less pharmacologically attributable adverse events (Odds ratio 0.62; 95% confidence interval, 0.46–0.82; P = 0.0007). There was difference between DOACs and conventional VTE prophylaxis regarding mortality, PE, symptomatic deep vein thrombosis, or bleeding events. The results generally support the use of DOACs for VTE prophylaxis after nonelective lower limb fracture surgery, such after hip fracture. The results more strongly support the use of XaIs; however, more evidence is needed to fully assess DOACs' role in clinical practice. Level of Evidence: Therapeutic Level II. See Instructions for Authors for a complete description of levels of evidence.]]> Tue 29 Nov 2022 10:42:17 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50863 Thu 17 Aug 2023 11:35:49 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:1671 Sat 24 Mar 2018 08:30:24 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:5095 Sat 24 Mar 2018 07:48:52 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48216 Mon 08 May 2023 14:35:50 AEST ]]>